TTPH:NAS (USA) Also trade in: Germany

Tetraphase Pharmaceuticals Inc

$ 1.06 -0.03 (-2.75%)
Volume: 845,538 Avg Vol (1m): 628,755
Market Cap $: 56.98 Mil Enterprise Value $: -22,510,000.00
P/E (TTM): 0.00 P/B: 0.74
Earnings Power Value -22.51
Net Current Asset Value 1.36
Tangible Book 1.4
Projected FCF -10.27
Median P/S Value 7.95
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 4/10

Current vs industry vs history
Cash-to-Debt 3.81
Equity-to-Asset 0.65
Debt-to-Equity 0.36
Debt-to-EBITDA -0.40
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -5.95
DISTRESS
GREY
SAFE
Beneish M-Score 9.33
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 15.51%

Profitability & Growth : 2/10

Current vs industry vs history
Operating Margin % -387.63
Net Margin % -381.69
ROE % -68.10
ROA % -56.85
ROC (Joel Greenblatt) % -5708.11
3-Year Total Revenue Growth Rate 17.40
3-Year Total EBITDA Growth Rate 5.00
3-Year EPS w/o NRI Growth Rate 16.60

» TTPH's 30-Y Financials

Financials (Next Earnings Date: 2019-05-03)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:TTPH

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare XPAR:IVA XTER:HAE XKRX:002800 XCNQ:IN XKRX:001360 OSTO:ORX NAS:GALT TSE:4539 HKSE:00911 ORSE:OLF1R LSE:SPH ROCO:4132 HKSE:06896 XKRX:131030 OTCPK:GSRX ROCO:6576 XKRX:009300 TPE:4119 XCNQ:TER OTCPK:CBIS
Traded in other countries 7TP.Germany
Address 480 Arsenal Street, Suite 110, Watertown, MA, USA, 02472
Tetraphase Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It creates novel antibiotics for serious and life-threatening multidrug-resistant infections. Its pipeline products are ERAVACYCLINE, TP-271, and TP-6076.

Ratios

Current vs industry vs history
PB Ratio 0.74
PS Ratio 2.93
EV-to-EBIT 0.28
EV-to-EBITDA 0.28
EV-to-Revenue -1.17
Current Ratio 7.78
Quick Ratio 7.73
Days Inventory 239.49
Days Sales Outstanding 43.90
Days Payable 5.00

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -12.80

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 0.76
Price-to-Median-PS-Value 0.13
Earnings Yield (Joel Greenblatt) % 321.72

More Statistics

Revenue (TTM) (Mil) $ 18.91
EPS (TTM) $ -1.37
Beta 2.57
Volatility % 65.07
52-Week Range $ 1.01 - 4.49
Shares Outstanding (Mil) 53.75

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y